Biopharmaceutical company Spectrum Pharmaceuticals, Inc., (Nasdaq:SPPI) said this morning that preclinical data on lucanthone suggest the orally administered small molecule inhibitor of DNA repair could potentially be used for the treatment of lung cancer.

Shares gained 7.6%, or $0.19, to $2.69 at 10 a.m. ET. For detailed price information and recent news stories about Spectrum Pharmaceuticals, click SPPI.